XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended
May 08, 2024
Apr. 01, 2024
Apr. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]          
Net impairment charge       $ 6,772,000  
Contingent consideration, current         $ 3,300,000
Finite-lived assets, net of accumulated amortization of $812 and $639, as of March 31, 2024 and December 31, 2023, respectively       28,245,000 41,871,000
Accumulated amortization       812,000 639,000
Contingent consideration, non-current       632,000 $ 1,172,000
2027 Term Loans | Subsequent Event          
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]          
Outstanding amount paid off $ 75,000,000.0 $ 175,000,000.0 $ 175,000,000.0    
Principal Amount   $ 250,000,000.0      
Surface Acquisition          
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]          
Contingent consideration, current       0  
Contingent consideration, current       0  
Contingent consideration, non-current       500,000  
Fair value of the contingent consideration       3,800,000  
Out-license - Novartis Institutes          
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]          
Impairment charge       10,600,000  
Out-license - Novartis Institutes | Surface Acquisition          
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]          
Impairment charge       10,600,000  
Net impairment charge       $ 6,800,000  
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]       Selling General And Administrative Expense